...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
【24h】

Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines

机译：靶向成纤维细胞生长因子受体（FGFR）和Medulloblastoma细胞系中的信号传导途径和磷酸膦酸3-激酶（PI3K）信号通路

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Medulloblastoma (MB) accounts for similar to 20% of pediatric malignant central nervous system tumors. Treatment strategies, including surgery, radiation therapy and/or chemotherapy, are effective, but recurrence and metastasis frequently occur. Therefore, novel therapies are required. Herein, the effects of fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) inhibitors on MB cells lines were evaluated. Materials and Methods: MB cell lines (UW228-3, DAOY, Med8a, D425, D283) were tested for sensitivity to FGFR (AZD4547) and PI3K (BEZ235 and BYL719) inhibitors by viability, cytotoxicity, apoptosis, and proliferation assays. Results: Single treatments with FGFR and PI3K inhibitors decreased viability and proliferation in a dose-dependent pattern in most cell lines. Combinination of the two type of drugs, increased sensitivity, especially of the most resistant cell line UW228-3. Conclusion: Combination treatments with FGFR and PI3K inhibitors were superior to single treatments with FGFR and PI3K inhibitors, especially with BEZ235, for MB cell
机译：背景/目的：Medulloblastoma（MB）占20％的儿科恶性中枢神经系统肿瘤。治疗策略，包括手术，放射治疗和/或化学疗法，是有效的，但经常发生复发和转移。因此，需要新的疗法。这里，评估成纤维细胞生长因子受体（FGFR）和磷酸膦酸酯3-激酶（PI3K）抑制剂对MB细胞系的影响。材料和方法：通过活力，细胞毒性，凋亡和增殖测定，测试对FGFR（AZD4547）和PI3K（BEZ235和BYL719）抑制剂的敏感性进行敏感性的MB细胞系（UW228-3，Daoy，Med8a，D425，D283）。结果：具有FGFR和PI3K抑制剂的单次处理在大多数细胞系中以剂量依赖性模式降低了活力和增殖。两种药物的组合，敏感性增加，尤其是最具抗性细胞系UW228-3。结论：FGFR和PI3K抑制剂的组合治疗优于单一处理FGFR和PI3K抑制剂，特别是BEZ235，用于MB细胞

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号